Rhenman & Partners Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Rhenman & Partners Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.21M	Sell	225,000 -80,000	-26%	-$725K	0.21%	88
2026 Q1	$2.58M	Buy	305,000 +40,000	+15%	+$381K	0.32%	76
2025 Q4	$3.22M	Buy	265,000 +63,000	+31%	+$765K	0.3%	76
2025 Q3	$2.36M	Buy	+202,000	New	+$2.42M	0.26%	82
2017 Q3	–	Sell	-40,000	Closed	-$371K	–	103
2017 Q2	$371K	Hold	40,000	–	–	0.05%	95
2017 Q1	$371K	Hold	40,000	–	–	0.06%	93
2016 Q4	$335K	Hold	40,000	–	–	0.06%	93
2016 Q3	$275K	Hold	40,000	–	–	0.04%	96
2016 Q2	$198K	Hold	40,000	–	–	0.04%	95
2016 Q1	$386K	Buy	+40,000	New	+$303K	0.08%	90

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rhenman & Partners Asset Management's OCUL Position: Q2 2026 in Review

Rhenman & Partners Asset Management reduced its Ocular Therapeutix (OCUL) stake by 26% in Q2 2026, selling an estimated $725K and leaving 225,000 shares worth $2.21M. The position accounts for 0.21% of the portfolio, ranked #88.

Rhenman & Partners Asset Management first reported a position in OCUL in Q1 2016 and has held it in 10 quarters since. The position peaked at $3.22M in Q4 2025. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Rhenman & Partners Asset Management held 225,000 shares of Ocular Therapeutix worth $2.21M as of Q2 2026.
Rhenman & Partners Asset Management sold 80,000 Ocular Therapeutix shares in Q2 2026, an estimated $725K.
Ocular Therapeutix made up 0.21% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #88 holding.
Rhenman & Partners Asset Management first reported a position in Ocular Therapeutix in Q1 2016 and has held it in 10 quarters since.
Rhenman & Partners Asset Management's Ocular Therapeutix position peaked at $3.22M in Q4 2025.
263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.